risks of glp 1 drugs GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment Long-Term Effects Of GLP-1 Medications:

Peptides 77 , 2837 (2016)

To help visualise the expected weight loss at different doses, let's look at this comparative table: These percentages represent average weight loss from baseline over a 68-72 week period, based on the SURMOUNT-1 trial for Mounjaro and the STEP-1 trial for Wegovy

Research on chromium supplementation has produced mixed results

447 Moreover, these agents promote hemodynamic equilibrium, 18 diminish thrombotic propensity, 448 alleviate endothelial oxidative stress, 449 attenuate inflammatory processes, 450 and foster a favorable balance of the gut microbiota, 451 all of which collectively contribute to the salutary effects of these agents in patients with AS